Emgality (galcanezumab) approved for migraine prevention in USA

Emgality (galcanezumab) 120 mg injection has been approved by the US Food and Drug Administration (FDA) for the preventive treatment of migraine in adults. The drug is available as a once-monthly, self-administered, subcutaneous injection. The recommended dose is 240 mg (two consecutive subcutaneous injections of 120 mg each) once as a loading dose, followed by monthly doses of 120 mg injected subcutaneously.

Read the full report here »